Skip to main content

SAB Biotherapeutics, Inc.

corporate_fare Company Profile

SAB Biotherapeutics, Inc.

SABS·NASDAQ·Life Sciences·CIK 0001833214

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company that develops multi-specific, high-potency human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's programs are based on mechanisms of action that have achieved proof-of-concept in clinical trials. SAB Biotherapeutics focuses on developing product candidates for disease targets where a differentiated approach can be either first-in-class against novel targets or best-in-class against complex targets, including type 1 diabetes (T1D) and other autoimmune disorders. Its lead candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach aimed at delaying onset and potentially preventing disease progression of Stage 3 T1D patients. The company uses advanced genetic engineering and antibody science to develop a proprietary technology capable of producing disease-targeted hIgG in large quantities without human plasma donors. This technology utilizes the human immune response to generate novel therapeutic candidates. SAB Biotherapeutics has optimized genetic engineering in the development of transchromosomic cattle, or Tc-Bovine™, to produce hIgG, with its production platform driving IgG1 production across its pipeline. This differentiated approach using polyclonal antibodies has no biosimilar pathway. The proprietary platform can generate additional novel therapeutic candidates by utilizing the human immune response to generate the optimal repertoire of hIgG for drug targets. The drug development production system generates a diverse repertoire of specifically targeted, high-potency hIgGs that can bind to multiple sites on targeted immunogens.

SAB Biotherapeutics, Inc. (NASDAQ:SABS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for SABS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for SABS spans 10-Q, 8-K, SCHEDULE 13D/A, 424B5.

Recent high-impact activity:

  • SAB Bio Q3 Loss Widens to $22.3M as R&D Spend Doubles; $205.3M Cash Covers One Year
  • SAB Biotherapeutics Secures FDA Fast Track for SAB-142 in Stage 3 Type 1 Diabetes
  • FDA Grants Fast Track to SAB-142 for New-Onset Type 1 Diabetes
  • SAB Biotherapeutics Reports Q2 Loss, Secures $101.8M in Offerings & Warrants with 75% Share Dilution
  • Breakthrough T1D Awards Grant to Support SAB-142 Clinical Study in Stage 3 Type 1 Diabetes

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$0
Net Income
$13.27M
Diluted EPS
-$0.79
Op. Cash Flow
-$44.78M
Free Cash Flow
-$45.71M
Operating Income
-$48.95M
Cash & Equivalents
$10.5M
Debt / Equity
0.00×
Shares Outstanding
47.61M sh
Source: 10-K · filed 2026-03-09 · accession 0001833214-26-000003

Short Interest & Short Volume

8.28 days to cover

FINRA reported short interest of 5,026,127 shares in SABS as of the October 30, 2026 settlement, a 4.7% increase from the prior period — about 8.3 days to cover at its recent average daily volume. On November 19, 2026, 25.4% of SABS volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)5,026,127 shares as of October 30, 2026
Change vs prior period▲ 4.7%
Days to cover8.28 at avg daily volume of 606,985
Daily short volume (FINRA facilities)25.4% of 800,038 shares on November 19, 2026
5-day average short volume50.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for SABS, detected from its recent SEC filings · based on capital-structure filings through 2026-08-06.

Significant Dilution from Capital Raises · Extended Cash Runway

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with S →
$2.73 -6.19% today
52-week range · as of 2026-11-05 $2.44 – $5.15
Market cap
$245.94M
Volume
39.2K (0.1× avg)
3-mo avg 689.2K
Live data · 2026-11-20 14:52 UTC · Market open

show_chartPrice Chart

Loading chart...

feed SABS - Latest Insights

SABS
Nov 05, 2026, 7:36 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.15
Real-time Price: $2.73 info
Change: -$0.420 (-13%) info
Market Cap: $245.943M info
SABS
Oct 13, 2026, 8:36 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.98
Real-time Price: $2.73 info
Change: -$0.2474 (-8%) info
Market Cap: $245.943M info
SABS
Oct 13, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.80
Real-time Price: $2.73 info
Change: -$0.070 (-2%) info
Market Cap: $245.943M info
SABS
Aug 06, 2026, 7:56 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.85
Real-time Price: $2.73 info
Change: -$1.12 (-29%) info
Market Cap: $245.943M info
SABS
Jul 07, 2026, 8:15 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.11
Real-time Price: $2.73 info
Change: -$1.38 (-34%) info
Market Cap: $245.943M info
SABS
Jul 07, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.11
Real-time Price: $2.73 info
Change: -$1.38 (-34%) info
Market Cap: $245.943M info
SABS
May 12, 2026, 7:35 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.67
Real-time Price: $2.73 info
Change: -$0.940 (-26%) info
Market Cap: $245.943M info
SABS
May 12, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $3.67
Real-time Price: $2.73 info
Change: -$0.940 (-26%) info
Market Cap: $245.943M info
SABS
May 04, 2026, 4:43 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $3.69
Real-time Price: $2.73 info
Change: -$0.960 (-26%) info
Market Cap: $245.943M info
SABS
May 04, 2026, 4:35 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.69
Real-time Price: $2.73 info
Change: -$0.960 (-26%) info
Market Cap: $245.943M info
SABS
Apr 22, 2026, 8:13 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.70
Real-time Price: $2.73 info
Change: -$0.970 (-26%) info
Market Cap: $245.943M info
SABS
Mar 23, 2026, 4:25 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $3.93
Real-time Price: $2.73 info
Change: -$1.20 (-31%) info
Market Cap: $245.943M info
SABS
Mar 18, 2026, 8:28 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.70
Real-time Price: $2.73 info
Change: -$0.9711 (-26%) info
Market Cap: $245.943M info
SABS
Mar 18, 2026, 8:26 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $3.70
Real-time Price: $2.73 info
Change: -$0.9711 (-26%) info
Market Cap: $245.943M info
SABS
Mar 17, 2026, 10:46 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.87
Real-time Price: $2.73 info
Change: -$1.14 (-29%) info
Market Cap: $245.943M info
SABS
Mar 17, 2026, 4:00 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $4.07
Real-time Price: $2.73 info
Change: -$1.34 (-33%) info
Market Cap: $245.943M info
SABS
Mar 11, 2026, 4:43 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $4.64
Real-time Price: $2.73 info
Change: -$1.91 (-41%) info
Market Cap: $245.943M info
SABS
Mar 10, 2026, 7:35 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.71
Real-time Price: $2.73 info
Change: -$0.980 (-26%) info
Market Cap: $245.943M info
SABS
Mar 09, 2026, 5:16 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.84
Real-time Price: $2.73 info
Change: -$1.11 (-29%) info
Market Cap: $245.943M info
SABS
Mar 09, 2026, 5:10 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $3.84
Real-time Price: $2.73 info
Change: -$1.11 (-29%) info
Market Cap: $245.943M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets